OTI-611

OTI-611 is an investigational **small-molecule inhibitor of chromodomain helicase DNA-binding protein 1-like** developed for oncology. In the cited preclinical breast cancer work, it is described as a CHD1L inhibitor that blocks CHD1L ATPase-dependent chromatin remodeling during the DNA damage response, traps CHD1L on chromatin, impairs H2AX phosphorylation, promotes PARP1 and PARP2 trapping at DNA damage sites, and induces **PARthanatos**. The reported activity was shown in triple-negative breast cancer models, where OTI-611 demonstrated single-agent cytotoxicity and synergy with PARP inhibitors and chemotherapy independent of BRCA mutation status, supporting its positioning as a targeted antineoplastic DNA damage response modulator.

Other names

CHD1Li OTI-611CHD-1Li OTI-611CHD 1Li OTI-611